Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer.
Saved in:
| Title: | Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer. |
|---|---|
| Authors: | Bagal SK; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Astles PC; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Diène C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Argyrou A; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Crafter C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Cassar DJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Fallan C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Hock A; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Jones T; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Moreau K; Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB4 0WG, U.K., Lamont GM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lamont S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Michaloglou C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Packer MJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Pike A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Ramos-Montoya A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Scott JS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Shaw J; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Shologu Z; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K. |
| Source: | Journal of medicinal chemistry [J Med Chem] 2024 Jul 25; Vol. 67 (14), pp. 11732-11750. Date of Electronic Publication: 2024 Jul 11. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38991141 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Bagal+SK%22">Bagal SK</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Astles+PC%22">Astles PC</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Diène+C%22">Diène C</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Argyrou+A%22">Argyrou A</searchLink>; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Crafter+C%22">Crafter C</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Cassar+DJ%22">Cassar DJ</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Fallan+C%22">Fallan C</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Hock+A%22">Hock A</searchLink>; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Jones+T%22">Jones T</searchLink>; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Moreau+K%22">Moreau K</searchLink>; Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Lamont+GM%22">Lamont GM</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Lamont+S%22">Lamont S</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Michaloglou+C%22">Michaloglou C</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Packer+MJ%22">Packer MJ</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Pike+A%22">Pike A</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Ramos-Montoya+A%22">Ramos-Montoya A</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Scott+JS%22">Scott JS</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Shaw+J%22">Shaw J</searchLink>; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, U.K.<br /><searchLink fieldCode="AU" term="%22Shologu+Z%22">Shologu Z</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229716531%22">Journal of medicinal chemistry</searchLink> [J Med Chem] 2024 Jul 25; Vol. 67 (14), pp. 11732-11750. <i>Date of Electronic Publication: </i>2024 Jul 11. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Chemical+Society%22">American Chemical Society </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9716531 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1520-4804 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200222623%22">00222623 </searchLink><i>NLM ISO Abbreviation: </i>J Med Chem <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38991141 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1021/acs.jmedchem.4c00269 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 11732 Titles: – TitleFull: Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Bagal SK – PersonEntity: Name: NameFull: Astles PC – PersonEntity: Name: NameFull: Diène C – PersonEntity: Name: NameFull: Argyrou A – PersonEntity: Name: NameFull: Crafter C – PersonEntity: Name: NameFull: Cassar DJ – PersonEntity: Name: NameFull: Fallan C – PersonEntity: Name: NameFull: Hock A – PersonEntity: Name: NameFull: Jones T – PersonEntity: Name: NameFull: Moreau K – PersonEntity: Name: NameFull: Lamont GM – PersonEntity: Name: NameFull: Lamont S – PersonEntity: Name: NameFull: Michaloglou C – PersonEntity: Name: NameFull: Packer MJ – PersonEntity: Name: NameFull: Pike A – PersonEntity: Name: NameFull: Ramos-Montoya A – PersonEntity: Name: NameFull: Scott JS – PersonEntity: Name: NameFull: Shaw J – PersonEntity: Name: NameFull: Shologu Z IsPartOfRelationships: – BibEntity: Dates: – D: 25 M: 07 Text: 2024 Jul 25 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1520-4804 Numbering: – Type: volume Value: 67 – Type: issue Value: 14 Titles: – TitleFull: Journal of medicinal chemistry Type: main |
| ResultId | 1 |